ZVRA — Zevra Therapeutics, Inc.

Summary of ZVRA Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $34.1 million, with $26.4 million from MIPLYFFA sales.
• Full Year 2025 Revenue: $106.5 million, primarily driven by MIPLYFFA ($87.4 million).
• Net Income: Q4 net income was $12.2 million ($0.20 per share), a significant improvement from a net loss of $35.7 million in Q4 2024. Full year net income was $83.2 million ($1.40 per share), compared to a net loss of $105.5 million in 2024.
• Operating Expenses: Q4 operating expenses were $23 million, down $1.5 million year-over-year. R&D expenses decreased to $2.6 million, while SG&A expenses increased to $20.4 million due to launch-related investments.
• Cash Position: As of December 31, 2025, cash and equivalents totaled $238.9 million, with total debt at approximately $61.9 million.

2. Strategic Updates and Business Highlights

• MIPLYFFA Performance: Strong commercial performance with 52 prescription enrollment forms in 2025, including 24 in Q4. Total enrollments since launch reached 161.
• Market Expansion: The company is pursuing a patent term extension for MIPLYFFA and expanding access through a global expanded access program (EAP) with 113 patients enrolled.
• European Market: Submitted a marketing authorization application to the European Medicines Agency (EMA) and is prepared to respond to regulatory questions. The company is also building relationships with key opinion leaders in Europe.
• Pipeline Development: Advancing Celiprolol for Vascular Ehlers-Danlos Syndrome (VEDS) with 52 patients enrolled in the ongoing Phase III DISCOVER study.

3. Forward Guidance and Outlook

• Growth Drivers: Anticipated continued growth in MIPLYFFA enrollments, particularly from newly diagnosed patients. The company expects variability in revenue due to the nature of the ultra-rare disease market.
• Market Potential: Management is optimistic about the addressable market for NPC, estimating between 300-900 diagnosed patients in the U.S. and continuing efforts to identify newly diagnosed patients.
• Investment Focus: Plans to prioritize investments in high-impact initiatives while exploring opportunities for pipeline expansion.

4. Bad News, Challenges, or Points of Concern

• Enrollment Variability: The company acknowledged potential variability in patient enrollment and revenue due to the nature of the ultra-rare disease market.
• Competition: Awareness of potential competition from other therapies, such as Mandos' adrabetadex for infantile onset NPC, which could impact MIPLYFFA's market position.
• Regulatory Risks: While the company is prepared for EMA questions, any unforeseen regulatory hurdles could delay market access in Europe.

5. Notable Q&A Insights

• Patient Identification: Management highlighted ongoing efforts to identify newly diagnosed patients through disease awareness campaigns and collaborations with genetic testing companies.
• Persistency Data: While it is too early to provide specific data on patient persistency on MIPLYFFA, refill rates are encouraging, indicating strong adherence.
• EAP Revenue Clarification: Q4 EAP revenue was driven by named patient sales, with expectations for variability in future quarters as the program stabilizes.
• Market Dynamics: The company is confident in its ability to capture a significant share of the diagnosed NPC patient population, with estimates suggesting they have engaged 40-50% of diagnosed patients.

Overall, Zevra's Q4 2025 results reflect strong financial performance and strategic initiatives aimed at expanding access to MIPLYFFA while navigating challenges inherent in the rare disease market.